Applied BioSystems and Millipore Fund Proteomics Project at the University of Tokyo.

Business Editors and Health/Medical Writers

BIOWIRE2K

FOSTER CITY, Calif. and TOKYO--(BW HealthWire)--Nov. 26, 2001

Applied Biosystems Japan, Ltd., a unit of Applied Biosystems Group (NYSE: ABI), an Applera Corporation business, and Nihon Millipore KK, a unit of Millipore Corporation (NYSE: MIL) today announced that they have jointly opened the Donation Department of Proteomics Research at the Institute of Medical Science at the University of Tokyo (IMSUT), with the support of IMSUT, represented by Dr. Kenichi Arai, Dean of IMSUT.

The Donation Department of Proteomics Research is a three-year project focused on developing new techniques for protein expression profiling and for the analysis of protein-to-protein interactions at the cellular level. The center was formed with the assistance of Dr. Kenichi Arai, Dean of IMSUT. Dr. Toshiaki Isobe, Visiting Professor of the University of Tokyo (at present, Professor at Tokyo Metropolitan University) will direct the new department. Dr. Isobe will facilitate cooperative projects in different research areas such as the expression and functional analysis of proteins, which require the development and fusion of various technologies from different research disciplines.

"The Donation Department of Proteomics Research represents a collaboration between academia and industry. The goal will be the creation of a technical platform for genome-based drug discovery," Dr. Arai said.

"By leveraging the combined expertise of all three collaborators, the formation of the Donation Department of Proteomics Research may lead to new technologies that could play a pivotal role in the acceleration of protein research," said Dr. Michael W. Hunkapiller, President of Applied Biosystems.

Fran Lunger, CEO and President of Millipore, said, "We're very pleased to be working with the University of Tokyo and our partner Applied Biosystems on this project. Life sciences research is a priority worldwide, and these relationships are effective in accelerating that important work."

About Applera Corporation and Applied Biosystems

Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation therapeutic discovery business. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for its own internal product development and for its customers, including collaboration partners and subscribers. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available on the World Wide Web at www.appliedbiosystems.com.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "expect" and "potential" among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) rapidly changing technology and dependence on development of new products; (2) significant overseas operations, with attendant exposure to fluctuations in the value of foreign currencies; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.

About Millipore

Millipore is a multinational, high technology company that provides technologies, tools and services for the development and production of new therapeutic drugs. It serves the life science research, biotechnology and pharmaceutical industries. For more information visit www.millipore.com.

Millipore Forward Looking Statement Disclaimer

The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, difficulties in the successful separation of the biosciences and microelectronics businesses; difficulties in the successful implementation of our restructuring activities; foreign exchange rates; increased regulatory concerns on the part of the biopharmaceutical industry; further consolidation of drug manufacturers; competitive factors such as new membrane technology; availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore's filings with the SEC.

Note to Editors: Applied Biosystems, Celera, Celera Diagnostics and Celera Genomics are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and certain other countries.